Finally, and importantly, it remains to be established if knowledge of either 2,3-DHBA or 2R-HG plasma levels has clinical implications for the treatment of AML in patients in addition to IDH1 or IDH2 genotype. The gene discussed is IDH2; the disease is acute myeloid leukemia.